Who is Susan Galbraith?

‍

‍

Susan Galbraith: Leading Oncology R&D with a Vision for Innovation and Mentorship

‍

‍

Susan Galbraith is the Executive Vice President of Oncology R&D at AstraZeneca, where she leads global efforts in cancer drug development. Since joining the company in 2010, she has overseen the successful launch of seven cancer treatments. Her scientific leadership is rooted in her clinical background as an oncologist, which informs her strategic direction in personalized cancer medicine. She plays a central role in advancing AstraZeneca’s oncology portfolio across multiple therapeutic areas.

‍

Her work emphasizes innovation in computational pathology and translational research, with a focus on making new therapies accessible to patients. Susan frequently highlights key milestones from internal research teams, offering detailed insights into mechanism-based drug targeting. Unlike general R&D leads, she uses her posts to connect molecular discoveries with real-world patient benefits. Her updates often feature scientific terms and clinical relevance, underscoring her dual expertise.

‍

‍

Susan is a vocal advocate for mentorship and gender equality in science, frequently engaging with initiatives that support women in STEM. She highlights the importance of diverse leadership in pharmaceutical innovation, reflecting her involvement on scientific boards and industry panels. Her content often features younger researchers or cross-disciplinary collaboration, signaling her long-term investment in the next generation of scientists. This positioning makes her both a leader and mentor in oncology R&D.

‍

In addition to AstraZeneca, she collaborates with organizations like the Union for International Cancer Control (UICC), amplifying global access to cancer care. Her recognition of external partnerships shows her belief in shared responsibility across institutions. She rarely posts personal content, keeping her tone professional and focused on tangible advancements in science. Her digital presence reflects a precise, measured communicator with impact at the highest levels of pharmaceutical research.

‍

‍

An Influencer Active on Social Media

‍

‍

Susan Galbraith is active on LinkedIn and X, with LinkedIn being her primary channel, where she maintains an authoritative and focused presence around oncology and drug development.

‍

‍

Susan's Social Media Strategy Analysis

‍

‍

LinkedIn: Where Susan Shares Oncology Innovation and STEM Advocacy

‍

‍

Susan Galbraith uses LinkedIn as her primary platform to share progress in oncology R&D, highlight institutional awards, and promote scientific collaboration. Her posts often feature formal recognitions—like AstraZeneca’s Prix Galien win—paired with team acknowledgments and research updates. Rather than speaking in generalities, she provides specific insights into drug mechanisms, clinical relevance, and therapeutic milestones. Her tone is professional yet warm, celebrating group achievements in cancer treatment development.

‍

She typically publishes three times per month, maintaining a steady rhythm that aligns with corporate communications and scientific event cycles. Her posts average 369 engagements and reach approximately 10K views, indicating consistent attention from a well-targeted audience of researchers, industry peers, and STEM advocates. Posts often appear at 7 AM EST, a time likely chosen to engage working professionals in biotech and pharma. She does not rely on viral content—each post is intentionally tied to a significant research or institutional moment.

‍

‍

Her visuals tend to include team event photos, award ceremonies, or branded institutional graphics, offering a behind-the-scenes view into AstraZeneca’s oncology efforts. Unlike creators who center their personal brand, Susan consistently centers the work of others—her teams, her institution, and cross-sector collaborators. These choices reinforce her image as a mentor and strategic leader in oncology rather than a solo voice.

‍

Her content is highly brand-safe, cheerfully optimistic, and politically neutral, which makes it ideal for institutions, academic partners, and STEM education advocates. Her consistent support of diversity in STEM and organizations like the Union for International Cancer Control reveals a pattern of aligning content with long-term impact. Each post advances not just science, but her broader mission of equity and innovation in global healthcare.

‍

• ‍Username: @susangalbraith584a195‍
• Influence Score: 89.8/100‍
• Followers: 10.5K‍
• Activity: 3 posts/month‍
• Engagement Rate: 3.51%‍
• Growth: +2.55%‍
• Average Engagement: 369‍
• Posting Habits: Once a week at 7 AM EST

‍

Recommended tools
‍Find LinkedIn influencers‍Analyze your own LinkedIn profile‍Analyze competitors' LinkedIn profiles

‍

X (formerly Twitter): Minimal Use for Visibility Only

‍

‍

Susan Galbraith maintains a profile on X (@susanmgalbraith), but it is inactive and holds no strategic role in her communication. With no posts in over two months and zero engagement in the last 30 days, this platform serves more as a public placeholder than an active channel. Her follower count remains modest at 1.1K, and she shows no recent history of interaction or content distribution.

‍

The profile has a minimal score of 5.7/100, with no recorded growth, posting activity, or community interaction. This is consistent with her preference for LinkedIn as a platform that supports in-depth scientific communication and team-focused updates. Unlike creators who leverage X for rapid thought bursts or event live-tweeting, Susan opts for more formal, complete reflections—better suited to her tone and professional role.

‍

• ‍Username: @susanmgalbraith‍
• Influence Score: 5.7/100‍
• Followers: 1.1K‍
• Activity: 0 tweets/week‍
• Engagement Rate: 0%‍
• Growth: 0%‍
• Average Engagement: 0‍
• Posting Habits: Once a year at 12 PM EST

‍

‍

Susan Galbraith's Social Media Influence Summary

‍

‍

Susan Galbraith has an Favikon Influence Score of 5,474 points, placing her in the Top 1% on LinkedIn UK (#314) and Top 5% in Health & Medical (UK, #627). She ranks in the Top 5% in Oncology & Cancer Worldwide (#636), demonstrating a strong authority within her field. Her influence is driven by high engagement (3.51%) and relevance to cancer innovation and mentorship—two themes tightly integrated into her profile.

‍

Learn more about the Favikon Methodology here

‍

Content Strategy: Advocacy Backed by Science

‍

Susan Galbraith’s content is grounded in scientific rigor, but her delivery is personable and supportive. She often credits team members, celebrates drug development milestones, and shares collaborative announcements involving AstraZeneca and partners like UICC. This balance of expert insight and team recognition builds trust across scientific and corporate audiences.

‍

‍

Reachability and Partnerships

‍

‍

Susan Galbraith is open to brand partnerships that align with her ongoing work in oncology innovation and STEM advocacy. She is most likely to engage in collaborations involving scientific recognition, award sponsorships, or educational campaigns that promote cancer research. Her estimated rate of $341–$417 per post reflects high trust and seniority in pharmaceutical R&D. Campaign formats that highlight institutional progress or team achievement are most relevant to her tone and posting style.

‍

‍

She frequently tags organizations like AstraZeneca and UICC, signaling a willingness to amplify aligned institutions and causes. Her audience includes R&D leaders, clinical researchers, and STEM professionals, making her ideal for B2B healthcare and science campaigns. She avoids casual promotions, so proposals must tie directly to cancer care, mentorship, or innovation. Speaking engagements, thought leadership features, and STEM advancement campaigns are strong entry points for collaboration.

‍

‍

Conclusion: A Scientific Leader with a Clear Public Voice

‍

Susan Galbraith’s digital presence reflects her senior role in oncology R&D and her genuine interest in mentorship and innovation. Though she’s selective in her activity, each post adds value—whether celebrating a medical breakthrough or promoting women in science. Her credibility stems not just from her title, but from the consistency and clarity of her voice.

‍

‍

View the AI-powered profile

‍

Also See 👀
‍DANIEL ABRAHAMS - COMPLETE SOCIAL MEDIA ANALYSIS‍ALICIA TELTZ - COMPLETE SOCIAL MEDIA ANALYSIS
‍🏆 TOP 200 INFLUENCERS WORLDWIDE